These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 2600942

  • 1. Treatment of refractory ischemic skin ulcers in patients with Raynaud's phenomenon with PGE1 infusions.
    Langevitz P, Buskila D, Lee P, Urowitz MB.
    J Rheumatol; 1989 Nov; 16(11):1433-5. PubMed ID: 2600942
    [Abstract] [Full Text] [Related]

  • 2. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
    Wigley FM, Seibold JR, Wise RA, McCloskey DA, Dole WP.
    J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
    [Abstract] [Full Text] [Related]

  • 3. Efficacy evaluation of prostaglandin E1 against placebo in patients with progressive systemic sclerosis and significant Raynaud's phenomenon.
    Bartolone S, Trifiletti A, De Nuzzo G, Scamardi R, Larosa D, Sottilotta G, Raffa A, Barbera N.
    Minerva Cardioangiol; 1999 May; 47(5):137-43. PubMed ID: 10479851
    [Abstract] [Full Text] [Related]

  • 4. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis.
    Gore J, Silver R.
    Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356
    [No Abstract] [Full Text] [Related]

  • 5. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
    Colakoğlu M, Cobankara V, Akpolat T.
    Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
    [Abstract] [Full Text] [Related]

  • 6. A multicenter double blind controlled study of lipo-PGE1, PGE1 incorporated in lipid microspheres, in peripheral vascular disease secondary to connective tissue disorders.
    Mizushima Y, Shiokawa Y, Homma M, Kashiwazaki S, Ichikawa Y, Hashimoto H, Sakuma A.
    J Rheumatol; 1987 Feb; 14(1):97-101. PubMed ID: 3553591
    [Abstract] [Full Text] [Related]

  • 7. Use of biofeedback training in treatment of Raynaud's disease and phenomenon.
    Yocum DE, Hodes R, Sundstrom WR, Cleeland CS.
    J Rheumatol; 1985 Feb; 12(1):90-3. PubMed ID: 3981523
    [Abstract] [Full Text] [Related]

  • 8. Effects of prostaglandin E1 on collagen diseases with high levels of circulating immune complexes.
    Yoshikawa T, Suzuki H, Kato H, Yano S.
    J Rheumatol; 1990 Nov; 17(11):1513-4. PubMed ID: 2273493
    [Abstract] [Full Text] [Related]

  • 9. [Effects of long-term iloprost therapy on Raynaud's phenomenon in progressive systemic sclerosis].
    Cordioli E, Virgilio S, Ghirardi R, Martinelli M.
    Minerva Med; 1992 Nov; 83(11):739-44. PubMed ID: 1281297
    [Abstract] [Full Text] [Related]

  • 10. Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study.
    Kawald A, Burmester GR, Huscher D, Sunderkötter C, Riemekasten G.
    J Rheumatol; 2008 Sep; 35(9):1830-7. PubMed ID: 18634152
    [Abstract] [Full Text] [Related]

  • 11. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
    Serri J, Legré R, Veit V, Guardia C, Gay AM.
    Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Raynaud, digital ulcers and calcinosis in scleroderma.
    Nitsche A.
    Reumatol Clin; 2012 Dec; 8(5):270-7. PubMed ID: 22835924
    [Abstract] [Full Text] [Related]

  • 14. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
    Abou-Raya A, Abou-Raya S, Helmii M.
    J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
    [Abstract] [Full Text] [Related]

  • 15. Intravenous N-acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study.
    Sambo P, Amico D, Giacomelli R, Matucci-Cerinic M, Salsano F, Valentini G, Gabrielli A.
    J Rheumatol; 2001 Oct; 28(10):2257-62. PubMed ID: 11669166
    [Abstract] [Full Text] [Related]

  • 16. Iloprost treatment in patients with Raynaud's phenomenon secondary to systemic sclerosis and the quality of life: a new therapeutic protocol.
    Milio G, Corrado E, Genova C, Amato C, Raimondi F, Almasio PL, Novo S.
    Rheumatology (Oxford); 2006 Aug; 45(8):999-1004. PubMed ID: 16484290
    [Abstract] [Full Text] [Related]

  • 17. [Sarpogrelate hydrochloride for Raynaud's phenomenon of patients with collagen diseases].
    Kumagai S, Morinobu A, Ozaki S, Nakao K, Ishida H.
    Ryumachi; 1998 Jun; 38(3):504-10. PubMed ID: 9721558
    [Abstract] [Full Text] [Related]

  • 18. A multiclinic, placebo-controlled, double-blind study of prostaglandin E1 in Raynaud's syndrome.
    Mohrland JS, Porter JM, Smith EA, Belch J, Simms MH.
    Ann Rheum Dis; 1985 Nov; 44(11):754-60. PubMed ID: 3904643
    [Abstract] [Full Text] [Related]

  • 19. [A case of systemic sclerosis in childhood complicated by severe digital ulcers].
    Falcini F, Volpi M, Pierattelli M, Taccetti G, Pratesi G, Matucci Cerinich M.
    Pediatr Med Chir; 1984 Nov; 6(5):703-7. PubMed ID: 6535137
    [Abstract] [Full Text] [Related]

  • 20. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis.
    Thompson AE, Shea B, Welch V, Fenlon D, Pope JE.
    Arthritis Rheum; 2001 Aug; 44(8):1841-7. PubMed ID: 11508437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.